(19)
(11) EP 3 676 247 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.04.2023 Bulletin 2023/15

(45) Mention of the grant of the patent:
08.03.2023 Bulletin 2023/10

(21) Application number: 18792709.0

(22) Date of filing: 01.10.2018
(51) International Patent Classification (IPC): 
C07C 309/82(2006.01)
A61P 31/04(2006.01)
 C07D 417/12(2006.01)
A61K 31/506(2006.01)
(52) Cooperative Patent Classification (CPC):
C07C 309/82; C07D 417/12; A61P 31/04; A61K 31/427; Y02A 50/30
(86) International application number:
PCT/US2018/053778
(87) International publication number:
WO 2019/070595 (11.04.2019 Gazette 2019/15)

(54)

AZTREONAM DERIVATIVES AND USES THEREOF

AZTREONAMDERIVATE UND VERWENDUNGEN DAVON

DÉRIVÉS D'AZTRÉONAM ET UTILISATIONS ASSOCIÉES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 02.10.2017 US 201762566909 P

(43) Date of publication of application:
08.07.2020 Bulletin 2020/28

(73) Proprietor: Arixa Pharmaceuticals, Inc.
New York, NY 10001-2192 (US)

(72) Inventors:
  • GORDON, Eric, M.
    Palo Alto, CA 94301 (US)
  • DUNCTON, Matthew, A.j.
    Palo Alto, CA 94301 (US)
  • FREUND, John
    Palo Alto, CA 94301 (US)

(74) Representative: Pfizer 
European Patent Department 23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14
75668 Paris Cedex 14 (FR)


(56) References cited: : 
   
  • MAREIKE KLINGER-STROBEL ET AL: "Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - where do we stand?", EXPERT OPINION ON DRUG DELIVERY, vol. 12, no. 8, 2 February 2015 (2015-02-02), pages 1351-1374, XP055524515, GB ISSN: 1742-5247, DOI: 10.1517/17425247.2015.1007949
  • DAVID HUTCHINSON ET AL: "Inhaled aztreonam lysine: an evidence-based review", EXPERT OPINION ON PHARMACOTHERAPY, vol. 14, no. 15, 31 August 2013 (2013-08-31), pages 2115-2124, XP055524539, LONDON, UK ISSN: 1465-6566, DOI: 10.1517/14656566.2013.831070
  • Aukje C. Bos ET AL: "Patient-Specific Modeling of Regional Antibiotic Concentration Levels in Airways of Patients with Cystic Fibrosis: Are We Dosing High Enough?", PLOS ONE, vol. 10, no. 3, 3 March 2015 (2015-03-03), page e0118454, XP055524514, DOI: 10.1371/journal.pone.0118454
  • I.M. Balfour-Lynn: "At last, Burkholderia spp. is one of the inclusion criteria ? A negative (but published) randomised controlled trial", Journal of Cystic Fibrosis, vol. 13, no. 3, 1 May 2014 (2014-05-01), pages 241-242, XP055524541, NL ISSN: 1569-1993, DOI: 10.1016/j.jcf.2014.01.003
  • ERIC M. GORDON ET AL: "Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2", ACS MEDICINAL CHEMISTRY LETTERS, vol. 11, 8 January 2020 (2020-01-08), pages 162-165,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).